Efficacy of Matrifen in Patients Older Than 18 Years With Severe, Chronic Pain

Matrifen for Therapy of Severe, Chronic Pain.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00556270

Acronym

MATRIX II

Enrollment

3000

Registered

2007-11-09

Start date

2007-11-30

Completion date

2008-05-31

Last updated

2012-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe, Chronic Pain

Keywords

pain, fentanyl, transdermal patch

Brief summary

The aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (WHO class 3).

Interventions

DRUGMatrifen

as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Main inclusion criteria: * Patients with severe, chronic pain Main

Exclusion criteria

* Hypersensitivity of fentanyl * Co-administration of monoaminooxidase-inhibitors * Pregnancy * Respiratory depression * Chronic obstructive pulmonary disease (COPD) * Drug abuse * Impairment of CNS functions * Other criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3)

Design outcomes

Primary

Measure	Time frame
Treatment success, efficacy of Matrifen	within 1 month

Secondary

Measure	Time frame
Safety and tolerability of fentanyl and the transdermal system, quality of life	within 1 month

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026